Prime Medicine, Inc. Financing Cash Flow
Prime Medicine, Inc. (PRME) reported Financing Cash Flow of $754.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Prime Medicine, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $361.00K, a 83.25% increase year-over-year.
- Prime Medicine, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $393.00K, a 93.45% decline year-over-year.
- Prime Medicine, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $562.00K, a 56100.00% increase year-over-year.
- Prime Medicine, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $144.75M, a 275.85% increase year-over-year.
- Prime Medicine, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $151.51M, a 22.65% decline from fiscal 2024.
- Prime Medicine, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $195.88M, a 29804.73% increase from fiscal 2023.
- Prime Medicine, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $655.00K, a 99.64% decline from fiscal 2022.
- Prime Medicine, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $181.49M, a 32.60% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $361.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $754.00K 10-Q · filed 2026-08-06 | $1.32M derived: sum of 3 quarters · filed 2026-08-06 | $146.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $393.00K 10-Q · filed 2026-05-07 | $955.00K derived: sum of 2 quarters · filed 2026-05-07 | $145.71M derived: sum of 3 quarters · filed 2026-05-07 | $145.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $562.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $145.31M derived: sum of 2 quarters · filed 2026-03-03 | $145.51M derived: sum of 3 quarters · filed 2026-08-06 | $151.51M 10-K · filed 2026-03-03 |
| 2025-09-30 | $144.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $144.95M derived: sum of 2 quarters · filed 2026-08-06 | $150.95M 10-Q · filed 2025-11-07 | $150.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.20M 10-Q · filed 2026-08-06 | $6.20M derived: sum of 3 quarters · filed 2026-08-06 | $44.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.00M 10-Q · filed 2026-05-07 | $6.00M derived: sum of 2 quarters · filed 2026-05-07 | $44.51M derived: sum of 3 quarters · filed 2026-05-07 | $44.55M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $38.51M derived: sum of 2 quarters · filed 2026-03-03 | $38.55M derived: sum of 3 quarters · filed 2026-03-03 | $195.88M 10-K · filed 2026-03-03 |
| 2024-09-30 | $38.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $38.55M derived: sum of 2 quarters · filed 2025-11-07 | $195.88M 10-Q · filed 2025-11-07 | $196.07M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $157.36M 10-Q · filed 2025-08-07 | $157.56M derived: sum of 3 quarters · filed 2025-08-07 | $157.87M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $157.33M 10-Q · filed 2025-05-08 | $157.52M derived: sum of 2 quarters · filed 2025-05-08 | $157.84M derived: sum of 3 quarters · filed 2025-05-08 | $157.91M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $512.00K derived: sum of 2 quarters · filed 2025-02-28 | $587.00K derived: sum of 3 quarters · filed 2025-02-28 | $655.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | $318.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $393.00K derived: sum of 2 quarters · filed 2024-11-12 | $461.00K 10-Q · filed 2024-11-12 | $184.53M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $143.00K 10-Q · filed 2024-08-08 | $184.22M derived: sum of 3 quarters · filed 2024-08-08 | $183.53M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $68.00K 10-Q · filed 2024-05-10 | $184.14M derived: sum of 2 quarters · filed 2024-05-10 | $183.46M derived: sum of 3 quarters · filed 2024-05-10 | $182.83M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $184.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $183.39M derived: sum of 2 quarters · filed 2024-03-01 | $182.77M derived: sum of 3 quarters · filed 2024-03-01 | $181.49M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$683.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$1.31M derived: sum of 2 quarters · filed 2023-11-03 | -$2.58M 10-Q · filed 2023-11-03 | -$3.67M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | -$624.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$1.90M 10-Q · filed 2023-08-07 | -$2.98M derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | -$1.27M 10-Q · filed 2023-05-11 | -$2.36M derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $269.28M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $270.36M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $34.93M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |